Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in:

Open Access 01-12-2024 | Coronary Heart Disease | Research

Rapid FEV1 decline and the effects of both FEV1 and FVC on cardiovascular disease: A UK biobank cohort analysis

Authors: Jiahui Zhang, Junru Wang, Xiaojun Ma, Yali Wang, Kai Liu, Zhuoyuan Li, Jing Wang, Lisha Na, Jiangping Li

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

The relationship between lung function and cardiovascular disease (CVD) has emerged as a significant research focus in recent years, but studies on the effects of both forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) remain limited.

Methods

Among 29,662 participants in the UK Biobank study free of CVD, rapid lung function decline was defined as the decline in either FEV1 (greatest quartile), FVC (greatest quartile), or both (when both FEV1 and FVC exceeded the greatest quartile). CVDs include coronary heart disease (CHD), arrhythmias, heart failure (HF), peripheral arterial disease (PAD), and other CVDs (including endocarditis, stroke, and myocardial diseases). Cox proportional hazards models were used to explore the associations between lung function and CVD incidence. Fine‒Gray models were used to account for the competing risk of death.

Results

Among 29,662 participants in the UK Biobank study free of CVD, the adjusted hazard ratios (HRs) for FEV1 rapid decline were 1.150 (95% CI: 1.009–1.311) for CHD, 1.307 (95% CI: 1.167–1.465) for arrhythmias, 1.406 (95% CI: 1.084–1.822) for HF, 1.287 (95% CI: 1.047–1.582) for PAD, 1.170 (95% CI: 1.022–1.340) for other CVDs, and 1.216 (95% CI: 1.124–1.315) for composite CVD. The adjusted HRs for the impact of both rapid decreases in FEV1 and FVC were 1.386 (95% CI: 1.226–1.567) for arrhythmias, 1.390 (95% CI: 1.041–1.833) for HF, 1.222 (95% CI: 1.054–1.417) for other CVDs, and 1.230 (95% CI: 1.128–1.340) for composite CVD.

Conclusions

The rapid decline in FEV1 and the impact of both FEV1 and FVC are closely associated with the subsequent incidence of various CVDs and composite CVD.
Appendix
Available only for authorised users
Literature
1.
Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–12.PubMedCrossRef
2.
Rod Jackson, Carlene MM, Lawes DA, Bennett RJ, Milne A. Treatment with drugs to lower blood cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–9.
3.
Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.PubMedCrossRef
4.
Maciej Polak A, Doryńska K, Szafraniec A, Pająk. Cardiovascular risk assessment, cardiovascular disease risk factors, and lung function parameters. Kardiol Pol. 2018;76(7):1055–63.PubMedCrossRef
5.
Eckhardt CM, Balte PP, Barr RG, et al. Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. Eur Heart J. 2022;43(23):2196–208.PubMedPubMedCentralCrossRef
6.
Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch Environ Health. 1970;21(3):418–24.PubMedCrossRef
7.
Higbee DH, Granell R, Sanderson E, Davey Smith G, Dodd JW. Lung function and cardiovascular disease: a two-sample Mendelian randomisation study. Eur Respir J. 2021;58(3):2003196.PubMedCrossRef
8.
Arcari A, Magnacca S, Bracone F, et al. Relation between pulmonary function and 10-year risk for cardiovascular disease among healthy men and women in Italy: the Moli-sani Project. Eur J Prev Cardiol. 2013;20(5):862–71.PubMedCrossRef
9.
10.
Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008;63(7):599–605.PubMedCrossRef
11.
Higbee DH, Granell R, Sanderson E, Davey Smith G, Dodd JW. Lung function and cardiovascular disease: a two-sample Mendelian randomisation study. Eur Respir J. 2021;58(3):2003196.PubMedCrossRef
12.
Nowak C. Lung Function and Coronary Artery Disease Risk. Circ Genom Precis Med. 2018;11(4):e002137.PubMedCrossRef
13.
Eckhardt CM, Balte PP, Barr RG, et al. Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. Eur Heart J. 2022;43(23):2196–208.PubMedPubMedCentralCrossRef
14.
Pan J, Xu L, Cai SX, et al. The association of pulmonary function with carotid atherosclerosis in older Chinese: Guangzhou Biobank Cohort Study-CVD Subcohort. Atherosclerosis. 2015;243(2):469–76.PubMedCrossRef
15.
Wielscher M, Amaral AFS, van der Plaat D, et al. Genetic correlation and causal relationships between cardio-metabolic traits and lung function impairment. Genome Med. 2021;13(1):104.PubMedPubMedCentralCrossRef
16.
Engström G, Lampa E, Dekkers K, et al. Pulmonary function and atherosclerosis in the general population: causal associations and clinical implications. Eur J Epidemiol. 2024;39(1):35–49.PubMedPubMedCentralCrossRef
17.
18.
Kang HK, Park HY, Jeong BH, Koh WJ, Lim SY. Relationship Between Forced Vital Capacity and Framingham Cardiovascular Risk Score Beyond the Presence of Metabolic Syndrome: The Fourth Korea National Health and Nutrition Examination Survey. Medicine (Baltimore). 2015;94(47):e2089.PubMedCrossRef
19.
Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–9.PubMedCrossRef
20.
21.
Baughman P, Marott JL, Lange P, et al. Combined effect of lung function level and decline increases morbidity and mortality risks. Eur J Epidemiol. 2012;27(12):933–43.PubMedCrossRef
22.
Zaigham S, Nilsson PM, Wollmer P, Engström G. The temporal relationship between poor lung function and the risk of diabetes. BMC Pulm Med. 2016;16(1):75.PubMedPubMedCentralCrossRef
23.
Zhou L, Yang H, Zhang Y, et al. Predictive value of lung function measures for cardiovascular risk: a large prospective cohort study. Thorax. 2024;79(3):250–8.PubMedCrossRef
24.
Han H, Cao Y, Feng C, et al. Association of a Healthy Lifestyle With All-Cause and Cause-Specific Mortality Among Individuals With Type 2 Diabetes: A Prospective Study in UK Biobank. Diabetes Care. 2022;45(2):319–29.PubMedCrossRef
25.
26.
Hancox RJ, Gray AR, Sears MR, Poulton R. Systemic inflammation and lung function: A longitudinal analysis. Respir Med. 2016;111:54–9.PubMedCrossRef
27.
Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 2015;6(3):209–17.PubMedPubMedCentralCrossRef
28.
Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009;179(1):35–40.PubMedCrossRef
29.
30.
Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2003;158(12):1171–81.PubMedCrossRef
31.
Au Yeung SL, Borges MC, Lawlor DA, Schooling CM. Impact of lung function on cardiovascular diseases and cardiovascular risk factors: a two sample bidirectional Mendelian randomisation study. Thorax. 2022;77(2):164–71.PubMedCrossRef
32.
Fan H, Xiong Y, Huang Y, et al. Lung function indices do not affect the incidence of coronary heart disease in patients with sleep-disordered breathing. Sleep Med. 2023;108:22–8.PubMedCrossRef
33.
Soler Artigas M, Loth DW, Wain LV, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet. 2011;43(11):1082–90. Published 2011 Sep 25.PubMedCrossRef
34.
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.PubMedCrossRef
35.
Bikov A, Lange P, Anderson JA, et al. FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1135–42. Published 2020 May 20.PubMedPubMedCentralCrossRef
36.
37.
Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS One. 2010;5(7):e11431.
38.
Ramalho SHR, Shah AM. Lung function and cardiovascular disease: A link. Trends Cardiovasc Med. 2021;31(2):93–8.PubMedCrossRef
39.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.PubMedCrossRef
40.
Whittaker HR, Bloom C, Morgan A, Jarvis D, Kiddle SJ, Quint JK. Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. Eur Respir J. 2021;57(3):2000918. Published 2021 Mar 4.PubMedPubMedCentralCrossRef
41.
Fabbri LM, Celli BR, Agustí A, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023;11(11):1020–34.PubMedCrossRef
42.
Agustí A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935–45.PubMedCrossRef
43.
Dale CE, Takhar R, Carragher R, et al. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management. Nat Med. 2023;29(1):219–25.PubMedCrossRef
44.
Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007;30(4):616–22.PubMedCrossRef
45.
Brayne C, Moffitt TE. The limitations of large-scale volunteer databases to address inequalities and global challenges in health and aging. Nat Aging. 2022;2(9):775–83.PubMedPubMedCentralCrossRef
Metadata
Title
Rapid FEV1 decline and the effects of both FEV1 and FVC on cardiovascular disease: A UK biobank cohort analysis
Authors
Jiahui Zhang
Junru Wang
Xiaojun Ma
Yali Wang
Kai Liu
Zhuoyuan Li
Jing Wang
Lisha Na
Jiangping Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-20716-1

Other articles of this Issue 1/2024

Prediction of individual, community and societal resilience in the Czech Republic compared to Slovakia during the war in Ukraine

Preconception care use and associated factors among HIV positive reproductive age women attending ART clinics at public hospitals in the Hadiya zone, southern Ethiopia: a mixed method approach

‘We get to learn as we move’: effects and feasibility of lesson-integrated physical activity in a Swedish primary school

  • Open Access
  • Research

Psychometric assessment of the Runyankole-translated Marlowe-Crowne Social Desirability Scale among persons with HIV in Uganda

Empowerment strategies of the Mentor Mother peer support program among mothers who have migrated to Sweden: a photovoice study

  • Open Access
  • Research

Evaluation of a school-based health education program on hepatitis B virus infection prevention practice in rural South-Western, Nigeria